查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1972732

镏-177市场：按产品类型、生产技术、应用、最终用户和分销管道分類的全球预测 - 2026年至2032年

Lutetium-177 Market by Product Type, Production Technology, Application, End-User, Distribution Channel - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 196 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2025 年，镏-177 市场价值将达到 10.5 亿美元，到 2026 年将成长到 12.3 亿美元，到 2032 年将达到 31.3 亿美元，年复合成长率为 16.76%。

主要市场统计数据
基准年 2025 10.5亿美元
预计年份：2026年 12.3亿美元
预测年份 2032 31.3亿美元
复合年增长率 (%) 16.76%

镏-177 全面概述：科学基础、临床前景、生产流程、法规环境及相关人员影响

镏-177已成为精准肿瘤学和核子医学交叉领域的关键放射性核素，推动了靶向分子配体与β射线同位素有效载荷相结合的新治疗方法趋势。过去十年，临床开发逐步证实了靶向放射性核素疗法的治疗潜力，吸引了临床医生、放射性药物专家和战略相关人员的广泛关注，他们都在寻求能够兼顾疾病控制和可控毒性的治疗方法。在生产和营运方面，镏-177带来了独特的复杂性，涉及同位素采购、放射性标记流程、低温运输物流以及跨司法管辖区的监管合规性。

一场变革性的转变正在重塑镏-177 的发展，涵盖科学创新、供应链现代化、监管演变和临床部署趋势。

镏-177领域正经历着一场变革性的转型，其驱动力来自科学技术创新、不断变化的监管环境以及自动化和供应链管理的进步。在科学方面，标靶配体和连接子化学的改进提高了肿瘤选择性和药物动力学特性，使更多类型的标靶得以研究。同时，更先进的剂量测定工具和影像生物标记的出现，使临床医生能够优化患者选择、制定个人化治疗方案、改善风险获益分析，并支持更广泛的临床应用。

评估美国关税于 2025 年生效对镏-177 进口、供应韧性、成本结构和战略应对措施的累积影响。

美国2025年实施的关税政策正促使处理镏-177的营业单位重新评估其筹资策略、供应商关係和製造地。关税的实施将透过关键生产过程的本地化和物流重组，为缓解不断增长的成本压力创造结构性奖励。实际上，这正促使各企业加快对国内放射性药物生产能力​​的投资，寻求与合约研发生产机构（CDMO）的区域合作，并探索分散同位素和前体来源（跨越多个供应商和司法管辖区）的对冲策略。

针对镏-177的商业化，将进行基于细分市场的分析，重点关注每种产品的形式、给药途径、目标疾病类别、自动化技术以及最终用户特征。

精准的细分观点揭示了商业性和临床机会与实际营运的交汇点，而理解这些细分领域对于制定有针对性的策略至关重要。产品类型（试剂盒和即用型製剂）的差异，为终端使用者带来了截然不同的工作流程。试剂盒强调现场放射性标记技术和灵活的给药方案，而即用型製剂则优先考虑便利性和简化的现场操作。给药途径仍是临床上的关键因素；肿瘤内给药可实现局部高剂量给药，而静脉注射支持全身性标靶治疗策略。每种给药途径对製剂、无菌性和临床监测都有其独特的要求。

镏-177区域策略展望引言：重点在于需求因素、基础设施差异、监管状况与区域合作机会

区域趋势显着影响相关人员进行临床部署、製造地和建立伙伴关係的方式，因此，基于地理因素的策略至关重要。在美洲，对专业癌症治疗中心和集中式放射性药物网络的投资，已构建起一个成熟的临床生态系统，为开展高级临床试验活动提供了支持，并为商业化铺平了道路。在该地区，结合临床支援和物流可靠性的综合解决方案往往更受欢迎，相关人员应优先考虑合作，以确保可预测的供应和流程培训，同时满足临床需求。

在镏-177价值链中营运的主要企业的竞争与合作概况（重点关注能力、伙伴关係关係、製造地和智慧财产权策略）

主要企业和机构正透过在放射化学、临床开发、生产规模和策略伙伴关係等方面的差异化能力，塑造竞争格​​局。在整个价值链中，一些机构专注于提供整合解决方案，将同位素生产与端到端的放射性标记服务和临床支援相结合，从而更严格地控製品质参数并确保供应的连续性。另一些机构则专注于提供模组化服务，例如客製化标记服务、集中式氯化镏-177供应或预标记治疗组件，使临床团队和中小企业能够在无需大量资本投入的情况下获得高品质产品。

为行业领导者提供切实可行的建议，以透过优化供应、临床合作、监管策略和商业性准备来加速镏-177 的应用。

业界领导企业可透过推动一系列切实可行的合作倡议，协调科学、监管和商业性需求，从而加速镏-177疗法的部署。首先，需要投资建构具有韧性的供应链结构，将本地放射性药物生产能力​​与策略性第三方伙伴关係关係结合，以减轻贸易政策变化和物流限制对营运的影响。其次，应优先推动自动化和标准化合成通讯协定，以减少放射性标记结果的差异，提高处理能力，并促进各生产设施符合法规要求。

透明的调查方法，解释了用于得出见解的主要和次要来源、检验程序、细分逻辑和分析框架。

本分析的研究途径结合了对同侪审查文献、监管指导文件、放射性药物生产技术标准的系统性回顾，以及对临床、生产和分销领域专家的定性访谈。对放射化学家、参与靶向放射性核素检测的临床研究人员、放射性药物部门负责人和供应链经理的访谈，旨在了解实际运作中的限制因素和新兴的最佳实践。二级资讯来源则提供了与镏-177应用相关的配体开发、剂量测定调查方法和稳定性概况等技术背景信息，从而补充了这些发现。

一份策略概要，概述了镏-177对相关人员的影响、当前挑战、新机会和短期行动重点。

总之，镏-177正处于一个策略转折点，科学成熟、营运创新和不断变化的政策环境在此交汇，为相关人员带来机会和挑战。从临床实验性化合物到临床规模治疗计画的转变，需要对可重复的生产、供应链的稳定性以及全面的临床证据的建立进行协调一致的投资。诸如监管差异、低温运输物流以及对训练有素的放射化学工程师的需求等持续存在的挑战，必须透过将商业性奖励与临床能力建设相结合的合作模式来解决。

目录

第一章：序言

第二章：调查方法

  • 调查设计
  • 研究框架
  • 市场规模预测
  • 数据三角测量
  • 调查结果
  • 调查的前提
  • 研究限制

第三章执行摘要

  • 首席主管观点
  • 市场规模和成长趋势
  • 2025年市占率分析
  • FPNV定位矩阵，2025
  • 新的商机
  • 下一代经营模式
  • 产业蓝图

第四章 市场概览

  • 产业生态系与价值链分析
  • 波特五力分析
  • PESTEL 分析
  • 市场展望
  • 上市策略

第五章 市场洞察

  • 消费者洞察与终端用户观点
  • 消费者体验基准
  • 机会映射
  • 分销通路分析
  • 价格趋势分析
  • 监理合规和标准框架
  • ESG与永续性分析
  • 中断和风险情景
  • 投资报酬率和成本效益分析

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

第八章：镏-177市场：依产品类型划分

  • 载体添加的镏-177
  • 不含载体的镏-177

第九章镏-177市场及其製造技术

  • 利用迴旋加速器法进行生产
  • 基于核子反应炉的生产

第十章：镏-177市场：依应用领域划分

  • 研究和临床前阶段
    • 体外研究
    • 体内动物模型
  • 治疗药物
    • 骨髓恶性肿瘤
    • 神经内分泌肿瘤（SSTRs）
    • 骨转移的安宁疗护
    • 前列腺癌（PSMA）

第十一章：镏-177市场：依最终用户划分

  • 医院
  • 门诊部
  • 製药和生物技术公司
  • 研究机构
  • 专科诊所

第十二章：镏-177市场：依通路划分

  • 直接购买
  • 间接

第十三章：镏-177市场：依地区划分

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十四章：镏-177市场：按组别划分

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十五章：镏-177市场：依国家划分

  • 我们
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十六章：美国镏-177市场

第十七章：中国的镏-177市场

第十八章 竞争情势

  • 市场集中度分析，2025年
    • 浓度比（CR）
    • 赫芬达尔-赫希曼指数 (HHI)
  • 近期趋势及影响分析，2025 年
  • 2025年产品系列分析
  • 基准分析，2025 年
  • Actinium Pharmaceuticals, Inc.
  • Bayer AG
  • BWX Technologies, Inc.
  • Cardinal Health, Inc.
  • China National Nuclear Corporation
  • Curium Pharma
  • Eckert & Ziegler Radiopharma GmbH
  • Framatome
  • Fusion Pharmaceuticals Inc. by AstraZeneca
  • IBA Radiopharma Solutions
  • Isotopia Molecular Imaging Ltd.
  • ITM Isotope Technologies Munich SE
  • Lantheus Holdings, Inc.
  • NorthStar Medical Radioisotopes, LLC
  • Novartis AG
  • NTP Radioisotopes SOC Ltd.
  • Nuclear Research and Consultancy Group
  • RadioMedix, Inc.
  • RayzeBio, Inc. by Bristol Myers Squibb
  • Revvity Inc.
  • SHINE Technologies, LLC
  • Telix Pharmaceuticals Limited
Product Code: MRR-9A6A6F2977DA

The Lutetium-177 Market was valued at USD 1.05 billion in 2025 and is projected to grow to USD 1.23 billion in 2026, with a CAGR of 16.76%, reaching USD 3.13 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 1.05 billion
Estimated Year [2026] USD 1.23 billion
Forecast Year [2032] USD 3.13 billion
CAGR (%) 16.76%

Comprehensive introduction to Lutetium-177: scientific foundations, clinical promise, manufacturing pathways, regulatory context and stakeholder implications

Lutetium-177 has emerged as a pivotal radionuclide at the intersection of precision oncology and nuclear medicine, driving a new wave of therapeutic modalities that couple targeted molecular ligands with beta-emitting isotope payloads. Over the past decade, clinical developments have progressively validated the therapeutic potential of targeted radionuclide therapies, increasing interest among clinicians, radiopharmacists, and strategic stakeholders who seek treatments that offer both disease control and manageable toxicity profiles. From a manufacturing and operational standpoint, Lutetium-177 introduces distinct complexities related to isotope sourcing, radiolabeling workflows, cold-chain logistics, and regulatory compliance across jurisdictions.

This introduction frames Lutetium-177 not only as a scientific asset but also as a commercial and logistical challenge that requires multidisciplinary coordination. Stakeholders must integrate clinical evidence, radiochemistry expertise, and supply chain design to transition candidates from preclinical validation into routine therapeutic use. Consequently, organizations pursuing opportunities in this space should prioritize reproducible radiolabeling processes, robust quality assurance practices, and proactive regulatory engagement to minimize translational friction and accelerate clinical adoption.

Transformative shifts reshaping Lutetium-177 development encompassing scientific innovations, supply chain modernization, regulatory evolution and clinical adoption dynamics

The landscape for Lutetium-177 is undergoing transformative shifts driven by converging scientific innovations, evolving regulatory frameworks, and advances in automation and supply chain orchestration. On the scientific front, improvements in targeting ligands and linker chemistry are yielding enhanced tumor selectivity and pharmacokinetic profiles, which in turn are expanding the range of target classes under investigation. Parallel to these advances, the emergence of more sophisticated dosimetry tools and imaging biomarkers is enabling clinicians to refine patient selection and personalize therapeutic regimens, thereby improving risk-benefit considerations and supporting broader clinical uptake.

Operationally, the field is moving toward modular and automated production models that reduce variability in radiolabeling and enable scalable, reproducible manufacturing across centralized and decentralized facilities. Regulatory pathways are adapting to accommodate the unique attributes of radiopharmaceuticals, with agencies clarifying expectations for sterility, radiochemical purity, and stability. These changes collectively reduce translational friction and invite new entrants, but they also raise competitive intensity around service capabilities, supply security, and integrated clinical support. As a result, the next phase of growth will favor organizations that can combine scientific differentiation with end-to-end operational excellence.

Assessing the cumulative consequences of United States tariffs effective in 2025 on Lutetium-177 imports, supply resilience, cost structures and strategic responses

The introduction of United States tariffs in 2025 has prompted a re-evaluation of procurement strategies, supplier relationships, and manufacturing footprints for entities engaged with Lutetium-177. Tariff impositions create a structural incentive to localize critical production steps or to reconfigure logistics to mitigate incremental cost pressures. In practice, this leads organizations to accelerate investments in domestic radiopharmacy capacity, to pursue regional partnerships with contract development and manufacturing organizations, and to explore hedging strategies that diversify isotope and precursor sourcing across multiple suppliers and jurisdictions.

Beyond cost implications, tariffs influence the cadence of strategic decision-making. Providers with long-term supply agreements and vertically integrated operations have greater flexibility to absorb transitional disruption, while smaller research centers and early-stage developers may face near-term access constraints that require operational adaptations such as shared radiochemistry facilities or collaboration with centralized compounding entities. Over time, policy-driven shifts will also shape competitive dynamics by altering the relative attractiveness of manufacturing investments in different regions and by incentivizing cross-border partnerships that internalize tariff impacts. Consequently, organizations should model tariff scenarios as part of their supply chain risk assessments and prioritize contingency plans that preserve clinical continuity and trial integrity.

Segment-driven insights for Lutetium-177 commercialization spotlighting product formats, routes of administration, target classes, automation and end-user nuances across offerings

A nuanced segmentation perspective reveals where commercial and clinical opportunities intersect with operational realities, and understanding these segments is essential for targeted strategy. Product type distinctions between Kits and Ready To Use formats create fundamentally different workflows for end users: kits emphasize on-site radiolabeling expertise and flexible scheduling, whereas ready-to-use formats prioritize convenience and reduced on-site complexity. Route of administration remains an important clinical axis, with intratumoral delivery enabling localized high-dose applications and intravenous administration supporting systemic targeting strategies; each route carries distinct requirements for formulation, sterility, and clinical monitoring.

Formulation choices between freeze-dried and liquid presentations influence stability, cold-chain logistics, and time-to-use constraints, thereby shaping distribution models and facility requirements. The product classification into Carrier-Added and No-Carrier-Added Lutetium-177 further stratifies the value chain: carrier-added variants and no-carrier-added variants each span custom labeling services, Lu-177 chloride intermediates, and pre-labeled therapeutic products, and these permutations affect regulatory pathways, radiochemical purity profiles, and end-user preparation needs. Target classes under investigation range from fibroblast activation protein, GRPR, and integrins to prostate-specific membrane antigen and somatostatin receptors; within those classes, PSMA-targeting approaches split into antibody-based constructs and small-molecule inhibitors, while somatostatin receptor-directed therapies predominantly utilize peptide analogues with defined pharmacokinetic behaviors.

End-user segmentation encompasses academic and research institutes, contract development and manufacturing organizations and contract research organizations, hospitals and cancer centers, nuclear medicine and radiopharmacy setups, and pharmaceutical and biotechnology companies. Hospitals and cancer centers exhibit a split between community care settings and tertiary care centers, each with varying procedural volumes and infrastructure. Nuclear medicine and radiopharmacy operations differentiate between centralized facilities that support multiple hospitals and on-site facilities embedded within clinical centers. Pharmaceutical and biotechnology firms include both generics and suppliers as well as innovators focused on novel radioligands. Automation level is another critical lens: fully automated synthesis platforms deliver consistency and throughput, semi-automated workflows balance flexibility and control, and manual labeling persists in low-volume or highly customized environments. A supplementary end-user view distinguishes hospitals from specialty clinics based on procedural complexity and case mix. Distribution channels fall into direct purchase and indirect pathways, with indirect distribution further bifurcated into retailer and wholesaler networks that influence inventory strategy and availability. Finally, application segmentation separates research and preclinical activities-including both in vitro studies and in vivo animal models-from therapeutic use cases that encompass hematologic malignancies, neuroendocrine tumors tied to somatostatin receptors, palliative treatments for bone metastases, and prostate cancer therapies centered on PSMA targeting. Together, these segmentation layers provide a multidimensional map for aligning product development, manufacturing design, reimbursement strategies, and clinical engagement plans.

Region-specific strategic outlook for Lutetium-177 deployment highlighting demand drivers, infrastructure gaps, regulatory landscapes and collaboration opportunities by geography

Regional dynamics materially influence how stakeholders approach clinical deployment, manufacturing placement, and partnership formation, and a geographically informed strategy is therefore indispensable. In the Americas, investment in specialized oncology centers and centralized radiopharmacy networks has created a mature clinical ecosystem that supports advanced trial activity and offers clear pathways for commercial rollout. This region tends to favor integrated solutions that combine clinical support with logistical reliability, and stakeholders should prioritize collaborations that ensure predictable supply and procedural training to capture clinical demand.

In Europe, the Middle East and Africa, regulatory heterogeneity and uneven infrastructure create both challenges and openings. Several countries in this broader region have advanced nuclear medicine capacities, but others require investment in cold-chain and sterile manufacturing to realize full clinical potential. Strategic entrants can benefit from phased approaches that combine centralized manufacturing hubs with capacity-building initiatives at tertiary care centers. Meanwhile, policy engagement with regional authorities is essential to streamline approvals and reimbursement frameworks.

The Asia-Pacific region is marked by rapid clinical adoption in select markets, growing pharmaceutical and radiochemistry expertise, and a growing appetite for local manufacturing to reduce import dependency. In several markets, strong public-sector investment in cancer care and localized clinical research programs presents opportunities for partnership and technology transfer. However, supply chain complexity and regulatory variance require tailored approaches that balance local production with regional distribution agreements. Across all regions, stakeholders should adapt strategies to local clinical pathways, regulatory expectations, and logistical realities while seeking scalable models that can be replicated across neighboring markets.

Competitive and collaborative profiles of key companies active in Lutetium-177 value chain emphasizing capabilities, partnerships, manufacturing footprints and IP positioning

Key corporate and institutional players are shaping the competitive topology through differentiated capabilities in radiochemistry, clinical development, manufacturing scale, and strategic partnerships. Across the value chain, some organizations emphasize integrated solutions that combine isotope production with end-to-end radiolabeling services and clinical support, enabling tighter control over quality parameters and supply continuity. Others specialize in modular service offerings-such as custom labeling services, centralized Lu-177 chloride supply, or pre-labeled therapeutic components-that allow clinical groups and smaller firms to access high-quality inputs without large capital outlays.

Collaboration patterns reveal a pragmatic orientation: alliances between research institutions, contract manufacturers, and clinical centers are accelerating trial execution and broadening access to complex radiotherapeutics. Intellectual property positioning centers on ligand chemistries, linker technologies, and manufacturing processes that improve radiochemical yield and stability. Meanwhile, firms that invest in automation and validated synthesis platforms secure operational advantages through reproducibility and throughput. For prospective partners and investors, evaluating company capabilities requires attention to manufacturing footprints, regulatory track records, clinical pipeline depth, and a demonstrated ability to scale from early-phase studies to routine therapeutic use. In short, the most compelling players combine technical depth with operational reliability and clear pathways to clinical adoption.

Actionable recommendations for industry leaders to accelerate Lutetium-177 adoption through supply optimization, clinical partnerships, regulatory strategy and commercial readiness

Industry leaders can accelerate adoption of Lutetium-177 therapies by pursuing a set of pragmatic, coordinated actions that align scientific, regulatory, and commercial imperatives. First, invest in resilient supply chain architectures that combine localized radiopharmacy capacity with strategic third-party partnerships to mitigate the operational impact of trade policy changes and logistical constraints. Second, prioritize automation and standardized synthesis protocols to reduce variability in radiolabeling outcomes, increase throughput, and facilitate regulatory compliance across sites.

Third, deepen clinical partnerships through joint protocols that validate dosimetry, patient selection criteria, and outcome measures; these collaborations will shorten time to evidence required for broader clinical acceptance. Fourth, design product portfolios that address distinct end-user needs by offering both kits for flexible on-site preparation and ready-to-use formats for centers seeking minimal operational burden. Fifth, proactively engage with regulatory authorities to clarify expectations for radiochemical characterization and sterility testing, and to streamline pathways for both carrier-added and no-carrier-added product variants. Finally, complement clinical and manufacturing investments with commercial enablement-educational programs for prescribing clinicians, reimbursement strategy development, and targeted distribution models-to ensure that supply and clinical capability translate into patient access and sustained utilization.

Transparent research methodology describing primary and secondary sources, validation steps, segmentation logic and analytical frameworks used to derive insights

The research approach underpinning this analysis combined systematic review of peer-reviewed literature, regulatory guidance documents, technical standards for radiopharmaceutical production, and qualitative interviews with domain experts across clinical, manufacturing, and distribution functions. Primary interviews focused on radiochemistry specialists, clinical investigators involved in targeted radionuclide trials, heads of radiopharmacy operations, and supply chain managers to capture real-world operational constraints and emerging best practices. Secondary sources complemented these insights by providing technical context on ligand development, dosimetry methodologies, and stability profiles relevant to Lutetium-177 applications.

Analytical rigor was ensured through cross-validation of qualitative inputs with documented procedural standards and publicly available clinical trial protocols. Segmentation logic was explicitly defined to reflect product format, route of administration, formulation, tracer class, end-user type, automation level, distribution channel, and application scope, allowing for layered analysis that connects technical attributes to operational and commercial implications. Where uncertainty existed, sensitivity checks and scenario analyses were used to delineate plausible outcomes and to highlight levers that stakeholders can influence to reduce execution risk. This methodological blend provides a robust foundation for the strategic recommendations and regional insights presented.

Concluding strategic synthesis summarizing Lutetium-177 implications for stakeholders, persistent challenges, emergent opportunities and priorities for near-term action

In conclusion, Lutetium-177 stands at a strategic inflection point where scientific maturation, operational innovation, and changing policy conditions converge to create both opportunity and complexity for stakeholders. The transition from investigational compounds to clinically scaled therapeutic programs requires coordinated investment in reproducible manufacturing, supply resilience, and comprehensive clinical evidence generation. Persistent challenges-such as regulatory heterogeneity, cold-chain logistics, and the need for trained radiochemistry personnel-must be addressed through collaborative models that align commercial incentives with clinical capacity-building.

Yet the opportunities are substantial: targeted radionuclide therapies have demonstrated potential across multiple target classes and indications, and advances in automation, dosimetry, and ligand chemistry continue to expand clinical applicability. Strategic actors that integrate technical differentiation with robust operational strategies and proactive regulatory engagement will be best positioned to capture value. The path forward demands disciplined execution, targeted partnerships, and an unwavering focus on translating clinical promise into accessible, reliable therapeutic options for patients.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Lutetium-177 Market, by Product Type

  • 8.1. Carrier-Added Lutetium-177
  • 8.2. No-Carrier-Added Lutetium-177

9. Lutetium-177 Market, by Production Technology

  • 9.1. Cyclotron-Based Production
  • 9.2. Reactor-Based Production

10. Lutetium-177 Market, by Application

  • 10.1. Research & Preclinical
    • 10.1.1. In Vitro Studies
    • 10.1.2. In Vivo Animal Models
  • 10.2. Therapeutics
    • 10.2.1. Hematologic Malignancies
    • 10.2.2. Neuroendocrine Tumors (SSTR)
    • 10.2.3. Palliative Bone Metastases
    • 10.2.4. Prostate Cancer (PSMA)

11. Lutetium-177 Market, by End-User

  • 11.1. Hospitals
  • 11.2. Outpatient Centers
  • 11.3. Pharmaceutical and Biotechnology Companies
  • 11.4. Research Institutions
  • 11.5. Specialty Clinics

12. Lutetium-177 Market, by Distribution Channel

  • 12.1. Direct Purchase
  • 12.2. Indirect

13. Lutetium-177 Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Lutetium-177 Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Lutetium-177 Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. United States Lutetium-177 Market

17. China Lutetium-177 Market

18. Competitive Landscape

  • 18.1. Market Concentration Analysis, 2025
    • 18.1.1. Concentration Ratio (CR)
    • 18.1.2. Herfindahl Hirschman Index (HHI)
  • 18.2. Recent Developments & Impact Analysis, 2025
  • 18.3. Product Portfolio Analysis, 2025
  • 18.4. Benchmarking Analysis, 2025
  • 18.5. Actinium Pharmaceuticals, Inc.
  • 18.6. Bayer AG
  • 18.7. BWX Technologies, Inc.
  • 18.8. Cardinal Health, Inc.
  • 18.9. China National Nuclear Corporation
  • 18.10. Curium Pharma
  • 18.11. Eckert & Ziegler Radiopharma GmbH
  • 18.12. Framatome
  • 18.13. Fusion Pharmaceuticals Inc. by AstraZeneca
  • 18.14. IBA Radiopharma Solutions
  • 18.15. Isotopia Molecular Imaging Ltd.
  • 18.16. ITM Isotope Technologies Munich SE
  • 18.17. Lantheus Holdings, Inc.
  • 18.18. NorthStar Medical Radioisotopes, LLC
  • 18.19. Novartis AG
  • 18.20. NTP Radioisotopes SOC Ltd.
  • 18.21. Nuclear Research and Consultancy Group
  • 18.22. RadioMedix, Inc.
  • 18.23. RayzeBio, Inc. by Bristol Myers Squibb
  • 18.24. Revvity Inc.
  • 18.25. SHINE Technologies, LLC
  • 18.26. Telix Pharmaceuticals Limited

LIST OF FIGURES

  • FIGURE 1. GLOBAL LUTETIUM-177 MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL LUTETIUM-177 MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL LUTETIUM-177 MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL LUTETIUM-177 MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL LUTETIUM-177 MARKET SIZE, BY PRODUCTION TECHNOLOGY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL LUTETIUM-177 MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL LUTETIUM-177 MARKET SIZE, BY END-USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL LUTETIUM-177 MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL LUTETIUM-177 MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL LUTETIUM-177 MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL LUTETIUM-177 MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. UNITED STATES LUTETIUM-177 MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 13. CHINA LUTETIUM-177 MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL LUTETIUM-177 MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL LUTETIUM-177 MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL LUTETIUM-177 MARKET SIZE, BY CARRIER-ADDED LUTETIUM-177, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL LUTETIUM-177 MARKET SIZE, BY CARRIER-ADDED LUTETIUM-177, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL LUTETIUM-177 MARKET SIZE, BY CARRIER-ADDED LUTETIUM-177, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL LUTETIUM-177 MARKET SIZE, BY NO-CARRIER-ADDED LUTETIUM-177, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL LUTETIUM-177 MARKET SIZE, BY NO-CARRIER-ADDED LUTETIUM-177, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL LUTETIUM-177 MARKET SIZE, BY NO-CARRIER-ADDED LUTETIUM-177, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL LUTETIUM-177 MARKET SIZE, BY PRODUCTION TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL LUTETIUM-177 MARKET SIZE, BY CYCLOTRON-BASED PRODUCTION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL LUTETIUM-177 MARKET SIZE, BY CYCLOTRON-BASED PRODUCTION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL LUTETIUM-177 MARKET SIZE, BY CYCLOTRON-BASED PRODUCTION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL LUTETIUM-177 MARKET SIZE, BY REACTOR-BASED PRODUCTION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL LUTETIUM-177 MARKET SIZE, BY REACTOR-BASED PRODUCTION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL LUTETIUM-177 MARKET SIZE, BY REACTOR-BASED PRODUCTION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL LUTETIUM-177 MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL LUTETIUM-177 MARKET SIZE, BY RESEARCH & PRECLINICAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL LUTETIUM-177 MARKET SIZE, BY RESEARCH & PRECLINICAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL LUTETIUM-177 MARKET SIZE, BY RESEARCH & PRECLINICAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL LUTETIUM-177 MARKET SIZE, BY RESEARCH & PRECLINICAL, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL LUTETIUM-177 MARKET SIZE, BY IN VITRO STUDIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL LUTETIUM-177 MARKET SIZE, BY IN VITRO STUDIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL LUTETIUM-177 MARKET SIZE, BY IN VITRO STUDIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL LUTETIUM-177 MARKET SIZE, BY IN VIVO ANIMAL MODELS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL LUTETIUM-177 MARKET SIZE, BY IN VIVO ANIMAL MODELS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL LUTETIUM-177 MARKET SIZE, BY IN VIVO ANIMAL MODELS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL LUTETIUM-177 MARKET SIZE, BY THERAPEUTICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL LUTETIUM-177 MARKET SIZE, BY THERAPEUTICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL LUTETIUM-177 MARKET SIZE, BY THERAPEUTICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL LUTETIUM-177 MARKET SIZE, BY THERAPEUTICS, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL LUTETIUM-177 MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL LUTETIUM-177 MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL LUTETIUM-177 MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL LUTETIUM-177 MARKET SIZE, BY NEUROENDOCRINE TUMORS (SSTR), BY REGION, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL LUTETIUM-177 MARKET SIZE, BY NEUROENDOCRINE TUMORS (SSTR), BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL LUTETIUM-177 MARKET SIZE, BY NEUROENDOCRINE TUMORS (SSTR), BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL LUTETIUM-177 MARKET SIZE, BY PALLIATIVE BONE METASTASES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL LUTETIUM-177 MARKET SIZE, BY PALLIATIVE BONE METASTASES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL LUTETIUM-177 MARKET SIZE, BY PALLIATIVE BONE METASTASES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL LUTETIUM-177 MARKET SIZE, BY PROSTATE CANCER (PSMA), BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL LUTETIUM-177 MARKET SIZE, BY PROSTATE CANCER (PSMA), BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL LUTETIUM-177 MARKET SIZE, BY PROSTATE CANCER (PSMA), BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL LUTETIUM-177 MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL LUTETIUM-177 MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL LUTETIUM-177 MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL LUTETIUM-177 MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL LUTETIUM-177 MARKET SIZE, BY OUTPATIENT CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL LUTETIUM-177 MARKET SIZE, BY OUTPATIENT CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL LUTETIUM-177 MARKET SIZE, BY OUTPATIENT CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL LUTETIUM-177 MARKET SIZE, BY PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL LUTETIUM-177 MARKET SIZE, BY PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL LUTETIUM-177 MARKET SIZE, BY PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL LUTETIUM-177 MARKET SIZE, BY RESEARCH INSTITUTIONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL LUTETIUM-177 MARKET SIZE, BY RESEARCH INSTITUTIONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL LUTETIUM-177 MARKET SIZE, BY RESEARCH INSTITUTIONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL LUTETIUM-177 MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL LUTETIUM-177 MARKET SIZE, BY SPECIALTY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL LUTETIUM-177 MARKET SIZE, BY SPECIALTY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL LUTETIUM-177 MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL LUTETIUM-177 MARKET SIZE, BY DIRECT PURCHASE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL LUTETIUM-177 MARKET SIZE, BY DIRECT PURCHASE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL LUTETIUM-177 MARKET SIZE, BY DIRECT PURCHASE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL LUTETIUM-177 MARKET SIZE, BY INDIRECT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL LUTETIUM-177 MARKET SIZE, BY INDIRECT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL LUTETIUM-177 MARKET SIZE, BY INDIRECT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL LUTETIUM-177 MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 67. AMERICAS LUTETIUM-177 MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 68. AMERICAS LUTETIUM-177 MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 69. AMERICAS LUTETIUM-177 MARKET SIZE, BY PRODUCTION TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 70. AMERICAS LUTETIUM-177 MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 71. AMERICAS LUTETIUM-177 MARKET SIZE, BY RESEARCH & PRECLINICAL, 2018-2032 (USD MILLION)
  • TABLE 72. AMERICAS LUTETIUM-177 MARKET SIZE, BY THERAPEUTICS, 2018-2032 (USD MILLION)
  • TABLE 73. AMERICAS LUTETIUM-177 MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 74. AMERICAS LUTETIUM-177 MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 75. NORTH AMERICA LUTETIUM-177 MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 76. NORTH AMERICA LUTETIUM-177 MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 77. NORTH AMERICA LUTETIUM-177 MARKET SIZE, BY PRODUCTION TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 78. NORTH AMERICA LUTETIUM-177 MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 79. NORTH AMERICA LUTETIUM-177 MARKET SIZE, BY RESEARCH & PRECLINICAL, 2018-2032 (USD MILLION)
  • TABLE 80. NORTH AMERICA LUTETIUM-177 MARKET SIZE, BY THERAPEUTICS, 2018-2032 (USD MILLION)
  • TABLE 81. NORTH AMERICA LUTETIUM-177 MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 82. NORTH AMERICA LUTETIUM-177 MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 83. LATIN AMERICA LUTETIUM-177 MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 84. LATIN AMERICA LUTETIUM-177 MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 85. LATIN AMERICA LUTETIUM-177 MARKET SIZE, BY PRODUCTION TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 86. LATIN AMERICA LUTETIUM-177 MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 87. LATIN AMERICA LUTETIUM-177 MARKET SIZE, BY RESEARCH & PRECLINICAL, 2018-2032 (USD MILLION)
  • TABLE 88. LATIN AMERICA LUTETIUM-177 MARKET SIZE, BY THERAPEUTICS, 2018-2032 (USD MILLION)
  • TABLE 89. LATIN AMERICA LUTETIUM-177 MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 90. LATIN AMERICA LUTETIUM-177 MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 91. EUROPE, MIDDLE EAST & AFRICA LUTETIUM-177 MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 92. EUROPE, MIDDLE EAST & AFRICA LUTETIUM-177 MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 93. EUROPE, MIDDLE EAST & AFRICA LUTETIUM-177 MARKET SIZE, BY PRODUCTION TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 94. EUROPE, MIDDLE EAST & AFRICA LUTETIUM-177 MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 95. EUROPE, MIDDLE EAST & AFRICA LUTETIUM-177 MARKET SIZE, BY RESEARCH & PRECLINICAL, 2018-2032 (USD MILLION)
  • TABLE 96. EUROPE, MIDDLE EAST & AFRICA LUTETIUM-177 MARKET SIZE, BY THERAPEUTICS, 2018-2032 (USD MILLION)
  • TABLE 97. EUROPE, MIDDLE EAST & AFRICA LUTETIUM-177 MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 98. EUROPE, MIDDLE EAST & AFRICA LUTETIUM-177 MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 99. EUROPE LUTETIUM-177 MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 100. EUROPE LUTETIUM-177 MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 101. EUROPE LUTETIUM-177 MARKET SIZE, BY PRODUCTION TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 102. EUROPE LUTETIUM-177 MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 103. EUROPE LUTETIUM-177 MARKET SIZE, BY RESEARCH & PRECLINICAL, 2018-2032 (USD MILLION)
  • TABLE 104. EUROPE LUTETIUM-177 MARKET SIZE, BY THERAPEUTICS, 2018-2032 (USD MILLION)
  • TABLE 105. EUROPE LUTETIUM-177 MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 106. EUROPE LUTETIUM-177 MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 107. MIDDLE EAST LUTETIUM-177 MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 108. MIDDLE EAST LUTETIUM-177 MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 109. MIDDLE EAST LUTETIUM-177 MARKET SIZE, BY PRODUCTION TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 110. MIDDLE EAST LUTETIUM-177 MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 111. MIDDLE EAST LUTETIUM-177 MARKET SIZE, BY RESEARCH & PRECLINICAL, 2018-2032 (USD MILLION)
  • TABLE 112. MIDDLE EAST LUTETIUM-177 MARKET SIZE, BY THERAPEUTICS, 2018-2032 (USD MILLION)
  • TABLE 113. MIDDLE EAST LUTETIUM-177 MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 114. MIDDLE EAST LUTETIUM-177 MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 115. AFRICA LUTETIUM-177 MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 116. AFRICA LUTETIUM-177 MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 117. AFRICA LUTETIUM-177 MARKET SIZE, BY PRODUCTION TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 118. AFRICA LUTETIUM-177 MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 119. AFRICA LUTETIUM-177 MARKET SIZE, BY RESEARCH & PRECLINICAL, 2018-2032 (USD MILLION)
  • TABLE 120. AFRICA LUTETIUM-177 MARKET SIZE, BY THERAPEUTICS, 2018-2032 (USD MILLION)
  • TABLE 121. AFRICA LUTETIUM-177 MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 122. AFRICA LUTETIUM-177 MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 123. ASIA-PACIFIC LUTETIUM-177 MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 124. ASIA-PACIFIC LUTETIUM-177 MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 125. ASIA-PACIFIC LUTETIUM-177 MARKET SIZE, BY PRODUCTION TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 126. ASIA-PACIFIC LUTETIUM-177 MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 127. ASIA-PACIFIC LUTETIUM-177 MARKET SIZE, BY RESEARCH & PRECLINICAL, 2018-2032 (USD MILLION)
  • TABLE 128. ASIA-PACIFIC LUTETIUM-177 MARKET SIZE, BY THERAPEUTICS, 2018-2032 (USD MILLION)
  • TABLE 129. ASIA-PACIFIC LUTETIUM-177 MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 130. ASIA-PACIFIC LUTETIUM-177 MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 131. GLOBAL LUTETIUM-177 MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 132. ASEAN LUTETIUM-177 MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 133. ASEAN LUTETIUM-177 MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 134. ASEAN LUTETIUM-177 MARKET SIZE, BY PRODUCTION TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 135. ASEAN LUTETIUM-177 MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 136. ASEAN LUTETIUM-177 MARKET SIZE, BY RESEARCH & PRECLINICAL, 2018-2032 (USD MILLION)
  • TABLE 137. ASEAN LUTETIUM-177 MARKET SIZE, BY THERAPEUTICS, 2018-2032 (USD MILLION)
  • TABLE 138. ASEAN LUTETIUM-177 MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 139. ASEAN LUTETIUM-177 MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 140. GCC LUTETIUM-177 MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 141. GCC LUTETIUM-177 MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 142. GCC LUTETIUM-177 MARKET SIZE, BY PRODUCTION TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 143. GCC LUTETIUM-177 MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 144. GCC LUTETIUM-177 MARKET SIZE, BY RESEARCH & PRECLINICAL, 2018-2032 (USD MILLION)
  • TABLE 145. GCC LUTETIUM-177 MARKET SIZE, BY THERAPEUTICS, 2018-2032 (USD MILLION)
  • TABLE 146. GCC LUTETIUM-177 MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 147. GCC LUTETIUM-177 MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 148. EUROPEAN UNION LUTETIUM-177 MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 149. EUROPEAN UNION LUTETIUM-177 MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 150. EUROPEAN UNION LUTETIUM-177 MARKET SIZE, BY PRODUCTION TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 151. EUROPEAN UNION LUTETIUM-177 MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 152. EUROPEAN UNION LUTETIUM-177 MARKET SIZE, BY RESEARCH & PRECLINICAL, 2018-2032 (USD MILLION)
  • TABLE 153. EUROPEAN UNION LUTETIUM-177 MARKET SIZE, BY THERAPEUTICS, 2018-2032 (USD MILLION)
  • TABLE 154. EUROPEAN UNION LUTETIUM-177 MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 155. EUROPEAN UNION LUTETIUM-177 MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 156. BRICS LUTETIUM-177 MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 157. BRICS LUTETIUM-177 MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 158. BRICS LUTETIUM-177 MARKET SIZE, BY PRODUCTION TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 159. BRICS LUTETIUM-177 MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 160. BRICS LUTETIUM-177 MARKET SIZE, BY RESEARCH & PRECLINICAL, 2018-2032 (USD MILLION)
  • TABLE 161. BRICS LUTETIUM-177 MARKET SIZE, BY THERAPEUTICS, 2018-2032 (USD MILLION)
  • TABLE 162. BRICS LUTETIUM-177 MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 163. BRICS LUTETIUM-177 MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 164. G7 LUTETIUM-177 MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 165. G7 LUTETIUM-177 MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 166. G7 LUTETIUM-177 MARKET SIZE, BY PRODUCTION TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 167. G7 LUTETIUM-177 MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 168. G7 LUTETIUM-177 MARKET SIZE, BY RESEARCH & PRECLINICAL, 2018-2032 (USD MILLION)
  • TABLE 169. G7 LUTETIUM-177 MARKET SIZE, BY THERAPEUTICS, 2018-2032 (USD MILLION)
  • TABLE 170. G7 LUTETIUM-177 MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 171. G7 LUTETIUM-177 MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 172. NATO LUTETIUM-177 MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 173. NATO LUTETIUM-177 MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 174. NATO LUTETIUM-177 MARKET SIZE, BY PRODUCTION TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 175. NATO LUTETIUM-177 MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 176. NATO LUTETIUM-177 MARKET SIZE, BY RESEARCH & PRECLINICAL, 2018-2032 (USD MILLION)
  • TABLE 177. NATO LUTETIUM-177 MARKET SIZE, BY THERAPEUTICS, 2018-2032 (USD MILLION)
  • TABLE 178. NATO LUTETIUM-177 MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 179. NATO LUTETIUM-177 MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 180. GLOBAL LUTETIUM-177 MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 181. UNITED STATES LUTETIUM-177 MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 182. UNITED STATES LUTETIUM-177 MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 183. UNITED STATES LUTETIUM-177 MARKET SIZE, BY PRODUCTION TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 184. UNITED STATES LUTETIUM-177 MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 185. UNITED STATES LUTETIUM-177 MARKET SIZE, BY RESEARCH & PRECLINICAL, 2018-2032 (USD MILLION)
  • TABLE 186. UNITED STATES LUTETIUM-177 MARKET SIZE, BY THERAPEUTICS, 2018-2032 (USD MILLION)
  • TABLE 187. UNITED STATES LUTETIUM-177 MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 188. UNITED STATES LUTETIUM-177 MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 189. CHINA LUTETIUM-177 MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 190. CHINA LUTETIUM-177 MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 191. CHINA LUTETIUM-177 MARKET SIZE, BY PRODUCTION TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 192. CHINA LUTETIUM-177 MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 193. CHINA LUTETIUM-177 MARKET SIZE, BY RESEARCH & PRECLINICAL, 2018-2032 (USD MILLION)
  • TABLE 194. CHINA LUTETIUM-177 MARKET SIZE, BY THERAPEUTICS, 2018-2032 (USD MILLION)
  • TABLE 195. CHINA LUTETIUM-177 MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 196. CHINA LUTETIUM-177 MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)